Duearity AB has today entered into an agreement with a distributor in the Netherlands who operates in Belgium, the Netherlands and Luxembourg. The distributor has evaluated Tinearity G1 and analyzed the conditions for the product in the three markets. Duearity is expected to enter into more distribution agreements and agreements with clinics in Europe and the United States in 2023 and 2024.
The distributor, Mediplast Benelux B.V., has evaluated Tinearity G1's conditions in Belgium, the Netherlands and Luxembourg. Among other things, statements from experts in tinnitus have been obtained. The conclusion is that Tinearity G1 has very good market conditions in the three countries. Marketing and sales will start in October 2023.
The distributor intends to carry out a pilot study which will be used as a basis in the application for Tinearity G1 to be included in the countries' subsidy systems.
The agreement is the company's third distributor agreement and Duearity AB thus covers Great Britain, Portugal, Belgium, the Netherlands and Luxembourg. The population of the five countries amounts to approximately 107 million people. Duearity will enter into more agreements in Europe and the US during 2023 and 2024.